Supernus wins US FDA nod for seizure drug
This article was originally published in Scrip
Executive Summary
Supernus Pharmaceuticals won US approval to market Oxtellar XR (SPN-804), its once-daily extended-release formulation of oxcarbazepine, an antiepileptic drug, as an adjunctive therapy to treat partial seizures in adults and in children as young as six years.